FDA clears Cymbalta to treat chronic musculoskeletal pain The U.S.
FDA clears Cymbalta to treat chronic musculoskeletal pain
The U.S. Food and Drug Administration today approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain. Cymbalta was first used to treat major depressive disorder in 2004.